Please ensure Javascript is enabled for purposes of website accessibility

Why TransEnterix Inc's Stock Is Being Obliterated Today

By Brian Feroldi - Apr 21, 2016 at 11:05AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Bummer news from the FDA sends shares into a tailspin.

Image source: Transenterix.

What: Shareholders of TransEnterix (ASXC -1.70%), a medical device company focused on robotic surgery, are having an awful day. TransEnterix's stock has shed more than 57% of its value as of 10:23 a.m. ET after the company announced that it received some disappointing news from the FDA. 

So what: TransEnterix stated last night that the FDA has outright rejected its 510(k) submission for its SurgiBot System. The agency stated that the data TransEnterix submitted for the SurgiBot System did not meet the criteria necessary to demonstrate a "substantial equivalence" to an already legally approved medical device. 

Given that the company's stock has been on fire in anticipation of receiving an approval, traders are reacting harshly to this news.

Now what: In the press release, TransEnterix's CEO Todd Pope stated:

The FDA's decision is extremely disappointing. We are in the process of reviewing all aspects of the FDA's communication

Pope also announced that they will give investors an overview of their regulatory strategy from here on their first-quarter conference call, which is scheduled for May 10.

While this news is definitely extremely disappointing, long-term investors should keep in mind that it doesn't necessarily mean the SurgiBot System will never win the market. In fact, the company has a handful of regulatory options from here.

The most likely path forward is that the company will gather new data on its system and then resubmit another 510(k) once they feel they have enough information to show a substantial equivalence. Another option -- though likely not a good one -- is to submit the device under a full premarket approval application, or PMA, which is typically a much lengthier and more arduous process then a 510(k) submission.

Of course, the downside to any of the company's options is that they will likely consume a considerable amount of time to complete, and even then, there is no guarantee of success. 

We already knew TransEnterix' stock was extremely risky, and this news makes the company's future far more difficult to predict. For that reason, I'm content to continue to watch this story unfold from the sidelines and suggest that you do the same. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Asensus Surgical, Inc. Stock Quote
Asensus Surgical, Inc.
ASXC
$0.39 (-1.70%) $0.01

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
345%
 
S&P 500 Returns
119%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/17/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.